Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab for localized dMMR colon cancer
2021-006046-12Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colon cancer, sponsored by Rigshospitalet. Primary endpoint: Pathological complete response. Started Nov 2021; status: completed.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2021-006046-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006046-12.